Acutus Medical Inc. [NASDAQ: AFIB] surged by $0.47 during the normal trading session on Monday and reaching a high of $1.215 during the day while it closed the day at $1.01. The company report on June 27, 2022 that Acutus Medical Announces FDA Clearance, Commercial Launch of AcQCross™ Line Extension Compatible with Watchman™ Delivery System.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Innovative Transseptal Access System Is First and Only to Feature Integrated Dilator and Needle to Reduce Exchanges.
Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the commercial launch of an expanded suite of left-heart access products to now include the AcQCross™ Qx system for use with the TruSeal (TM) and FXD(TM) delivery system for the Watchman™ LAAC Device.
Acutus Medical Inc. stock has also gained 105.66% of its value over the past 7 days. However, AFIB stock has declined by -43.58% in the 3 months of the year. Over the past six months meanwhile, it has lost -71.87% and lost -70.38% year-on date.
The market cap for AFIB stock reached $29.29 million, with 28.12 million shares outstanding and 26.24 million shares in the current float. Compared to the average trading volume of 1.92M shares, AFIB reached a trading volume of 140125006 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Acutus Medical Inc. [AFIB]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AFIB shares is $3.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AFIB stock is a recommendation set at 2.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for Acutus Medical Inc. shares, keeping their opinion on the stock as Underweight, with their previous recommendation back on November 15, 2021. While these analysts kept the previous recommendation, Goldman raised their target price to Neutral. The new note on the price target was released on October 22, 2021, representing the official price target for Acutus Medical Inc. stock. Previously, the target price had yet another raise from $11 to $18, while Canaccord Genuity kept a Buy rating on AFIB stock. On March 19, 2021, analysts decreased their price target for AFIB shares from 39 to 19.
The Average True Range (ATR) for Acutus Medical Inc. is set at 0.12, with the Price to Sales ratio for AFIB stock in the period of the last 12 months amounting to 1.68. The Price to Book ratio for the last quarter was 0.41, with the Price to Cash per share for the same quarter was set at 2.57.
AFIB stock trade performance evaluation
Acutus Medical Inc. [AFIB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 105.66. With this latest performance, AFIB shares gained by 49.41% in over the last four-week period, additionally sinking by -71.87% over the last 6 months – not to mention a drop of -94.28% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AFIB stock in for the last two-week period is set at 68.82, with the RSI for the last a single of trading hit 79.14, and the three-weeks RSI is set at 59.92 for Acutus Medical Inc. [AFIB]. The present Moving Average for the last 50 days of trading for this stock 0.8015, while it was recorded at 0.6412 for the last single week of trading, and 3.4478 for the last 200 days.
Acutus Medical Inc. [AFIB]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Acutus Medical Inc. [AFIB] shares currently have an operating margin of -671.19 and a Gross Margin at -90.73. Acutus Medical Inc.’s Net Margin is presently recorded at -681.71.
Return on Equity for this stock declined to -101.32, with Return on Assets sitting at -64.96.
Acutus Medical Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.00 and a Current Ratio set at 6.00.
Acutus Medical Inc. [AFIB]: Insider Ownership positions
There are presently around $9 million, or 62.80% of AFIB stock, in the hands of institutional investors. The top three institutional holders of AFIB stocks are: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) with ownership of 2,648,386, which is approximately 0% of the company’s market cap and around 1.50% of the total institutional ownership; ORBIMED ADVISORS LLC, holding 2,648,386 shares of the stock with an approximate value of $1.43 million in AFIB stocks shares; and CAPITAL WORLD INVESTORS, currently with $0.86 million in AFIB stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Acutus Medical Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 28 institutional holders increased their position in Acutus Medical Inc. [NASDAQ:AFIB] by around 1,723,786 shares. Additionally, 49 investors decreased positions by around 3,600,720 shares, while 10 investors held positions by with 10,672,423 shares. The mentioned changes placed institutional holdings at 15,996,929 shares, according to the latest SEC report filing. AFIB stock had 14 new institutional investments in for a total of 862,269 shares, while 23 institutional investors sold positions of 550,877 shares during the same period.